Last reviewed · How we verify
Pandel Cream 0.1%
At a glance
| Generic name | Pandel Cream 0.1% |
|---|---|
| Sponsor | Fougera Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (PHASE3)
- A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD (PHASE4)
- Local Steroid Treatment for Idiopathic Granulomatous Mastitis (LSTIGM) (PHASE4)
- Radiotherapy Related Skin Toxicity: Mepitel® vs. Standard Care in Patients With Locally Advanced Head-and-Neck Cancer (NA)
- A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis (PHASE2)
- Evaluation of the Vasoconstriction Properties of MC2-01 Cream (PHASE1)
- Efficacy and Steroid Sparing Potential Study of DGLA Cream in Early Childhood Patients With Moderate to Severe Atopic Dermatitis (PHASE2)
- Medical and Surgical Treatment for Idiopathic Granulomatous Mastitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pandel Cream 0.1% CI brief — competitive landscape report
- Pandel Cream 0.1% updates RSS · CI watch RSS
- Fougera Pharmaceuticals Inc. portfolio CI